U.S.-based medical technology company Nico Corp has scored $13 million in funding round.
With the capital raised, Nico Corp intends to enhance new product development and commercialization, additional clinical studies in tissue collection and biological preservation for personalized medicine research initiatives.
Additionally, the company also plans to use the part of the proceeds to boost sales and clinical team growth, and geographic expansion initially within Europe.
Since inception, Nico Corp has closed $49.5 million in funding round.